What is the current evidence‑based recommendation for prescribing sublingual nitroglycerin (0.3‑0.4 mg tablet or 0.4 mg spray) at discharge from the emergency department for an adult patient with anginal chest pain, including dosing, contraindications, monitoring parameters, patient education, and follow‑up?

Sublingual Nitroglycerin at Emergency Department Discharge

Direct Recommendation

All patients discharged from the emergency department after evaluation for non-ST-elevation acute coronary syndrome (NSTE-ACS) or anginal chest pain must be prescribed sublingual or spray nitroglycerin with comprehensive verbal and written instructions for its use. 1

---

Prescription Requirements

Formulation and Dosing

• Prescribe either sublingual tablets (0.3–0.4 mg) or spray (0.4 mg) 1, 2
• The spray formulation may be superior in patients with dry mouth, as it achieves faster symptom relief when oral moisture is decreased 3
• Instruct patients to dissolve one tablet under the tongue or administer one spray dose at the first sign of anginal discomfort 2
• Doses may be repeated every 5 minutes for up to 3 total doses 1, 2

Critical Patient Instructions (Class I Recommendation)

For acute anginal episodes lasting more than 1 minute:

• Take 1 dose of sublingual nitroglycerin immediately 1
• If chest discomfort is unimproved or worsening after 5 minutes following the first dose, call 9-1-1 immediately to access emergency medical services 1
• While awaiting EMS, up to 2 additional doses may be taken at 5-minute intervals (for a total of 3 doses) 1

This represents a critical update from older protocols: The emphasis is now on calling 9-1-1 after the first dose if pain does not subside, rather than waiting until after 3 doses have failed. 1 This change prioritizes earlier activation of emergency services for potential acute coronary syndrome.

---

Prophylactic Use

• Patients should be instructed that nitroglycerin may be used prophylactically 5–10 minutes before activities known to precipitate angina (e.g., exertion, cold exposure, emotional stress) 2
• This preventive strategy is often overlooked but represents an important component of angina self-management 4

---

Absolute Contraindications

Phosphodiesterase-5 Inhibitors

• Never prescribe nitroglycerin to patients who have used sildenafil or vardenafil within 24 hours or tadalafil within 48 hours 1, 2
• This combination can cause life-threatening hypotension, myocardial infarction, or sudden death 1
• Explicitly document this contraindication and provide written instructions to the patient 1

Hemodynamic Contraindications

• Do not administer if systolic blood pressure is <90 mmHg or ≥30 mmHg below the patient's baseline 1, 2
• Avoid in patients with severe bradycardia (<50 bpm) or marked tachycardia (>100 bpm) in the absence of heart failure 1
• Exercise extreme caution in suspected right ventricular infarction (particularly with inferior wall MI); nitroglycerin can precipitate profound hypotension in this setting 1

Other Contraindications

• Hypertrophic cardiomyopathy (nitrates may worsen outflow obstruction) 2
• Known hypersensitivity to nitrates 2

---

Storage and Shelf-Life Education

Critical Storage Instructions

• Nitroglycerin tablets must be kept in the original glass container with the cap tightly closed after each use to prevent loss of potency 2
• Tablets have a shelf life of only 6 months after first opening the bottle 5
• Spray formulations have a longer shelf life of 2 years after first use 5

Common Pitfall

Research demonstrates that 91.8% of patients prescribed sublingual nitroglycerin tablets do not know the shelf-life, and 35.6% of patients routinely carrying nitroglycerin have an expired product. 5 This represents a critical gap in patient education that must be addressed at discharge.

---

Patient Education Requirements (Class I Recommendations)

Mandatory Verbal and Written Instructions Must Include:

Medication-Specific Information:

• Exact dose, frequency, and administration technique (sublingual placement, not swallowing) 1, 2
• Expected effects: burning or tingling sensation under the tongue (though absence does not indicate loss of potency) 2
• Common side effects: headache (may indicate drug activity), lightheadedness, dizziness 2
• Storage requirements and shelf-life 2, 5

Safety Precautions:

• Sit down when taking nitroglycerin and use caution when standing to prevent falls from orthostatic hypotension 2
• Avoid alcohol, which potentiates hypotensive effects 2
• Carry nitroglycerin at all times 6

When to Seek Emergency Care:

• Call 9-1-1 if chest pain does not improve within 5 minutes after the first dose 1
• Call 9-1-1 if pain is different in character than typical angina 1, 2
• Contact physician without delay if angina pattern changes (more frequent, more severe, precipitated by less effort, or occurs at rest) 1

---

Concurrent Discharge Medications

Anti-Ischemic Therapy Continuation

• All medications used in-hospital to control ischemia should be continued after discharge in patients with NSTE-ACS who did not undergo revascularization, had incomplete revascularization, or have recurrent symptoms 1
• Dose titration may be required in the outpatient setting 1

Mandatory Antiplatelet Therapy

• Aspirin 81 mg daily (indefinitely) in patients treated with ticagrelor, or 81–325 mg daily in all other patients 1
• Continue prescribed P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) for the recommended duration 1

---

Monitoring and Follow-Up Parameters

Immediate Post-Discharge Period

• Patients must understand that worsening or changing anginal patterns require immediate physician contact to assess need for additional testing or treatment 1
• Schedule cardiology follow-up within 1–2 weeks of discharge for medication optimization and risk stratification 1

Long-Term Monitoring

• Assess nitroglycerin use frequency at each visit; increasing frequency suggests inadequate background anti-anginal therapy 1
• Verify that patients are carrying non-expired nitroglycerin 5
• Reinforce proper use instructions, as knowledge deficits are common even in patients with longstanding angina 6, 4

---

Common Prescribing Gaps and How to Avoid Them

Underprescription Problem

Despite guideline recommendations, 37–54% of patients with documented coronary artery disease and angina are not prescribed sublingual nitroglycerin at discharge. 5, 6 This represents a significant quality gap in care.

Solution: Implement systematic discharge order sets that automatically include sublingual nitroglycerin for all patients evaluated for ACS or angina. 5

Inadequate Patient Education

Only 43–66% of patients prescribed nitroglycerin receive instruction on its proper use from their physician. 1, 6, 4

Solution: Provide standardized, written discharge instructions in plain language that cover all key education points listed above. 1 Verbal reinforcement by nursing staff or pharmacists before discharge is essential. 1

Failure to Address Prophylactic Use

Many patients are unaware that nitroglycerin can be used preventively before activities that trigger angina. 4

Solution: Explicitly instruct patients to take nitroglycerin 5–10 minutes before planned exertion or other known triggers. 2

---

Evidence Quality and Strength

The recommendation to prescribe sublingual nitroglycerin at discharge for all post-NSTE-ACS patients is a Class I recommendation (should be performed) with Level of Evidence C (based on expert consensus and pathophysiologic rationale). 1 While randomized trial data specifically examining discharge nitroglycerin prescribing are limited, the recommendation is supported by decades of clinical experience, established pharmacologic mechanisms, and consistent guideline consensus across multiple iterations of ACC/AHA guidelines. 1